Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings
Open Access
- 14 August 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (16) , 4087-4094
Abstract
Purpose: To evaluate germline variants in hereditary cancer susceptibility genes among unselected cancer patients undergoing tumor–germline sequencing. Experimental Design: Germline sequence data from 439 individuals undergoing tumor–germline dyad sequencing through the LCCC1108/UNCseq™ (NCT01457196) study were analyzed for genetic variants in 36 hereditary cancer susceptibility genes. These variants were analyzed as an exploratory research study to determine whether pathogenic variants exist within the germline of patients undergoing tumor–germline sequencing. Patients were unselected with respect to indicators of hereditary cancer predisposition. Results: Variants indicative of hereditary cancer predisposition were identified in 19 (4.3%) patients. For about half (10/19), these findings represent new diagnostic information with potentially important implications for the patient and their family. The others were previously identified through clinical genetic evaluation secondary to suspicion of a hereditary cancer predisposition. Genes with pathogenic variants included ATM, BRCA1, BRCA2, CDKN2A, and CHEK2. In contrast, a substantial proportion of patients (178, 40.5%) had Variants of Uncertain Significance (VUS), 24 of which had VUS in genes pertinent to the presenting cancer. Another 143 had VUS in other hereditary cancer genes, and 11 had VUS in both pertinent and nonpertinent genes. Conclusions: Germline analysis in tumor–germline sequencing dyads will occasionally reveal significant germline findings that were clinically occult, which could be beneficial for patients and their families. However, given the low yield for unexpected germline variation and the large proportion of patients with VUS results, analysis and return of germline results should adhere to guidelines for secondary findings rather than diagnostic hereditary cancer testing. Clin Cancer Res; 22(16); 4087–94. ©2016 AACR. See related commentary by Mandelker, p. 3987Keywords
Funding Information
- Cancer Research NIH (U01 HG006487)
This publication has 44 references indexed in Scilit:
- Who is being referred to cancer genetic counseling? Characteristics of counselees and their referralJournal of Community Genetics, 2012
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudyScience Translational Medicine, 2011
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecologic Oncology, 2011
- Advances in understanding cancer genomes through second-generation sequencingNature Reviews Genetics, 2010
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics ClinicDiseases of the Colon & Rectum, 2008
- Is CHEK2 a cause of the Li–Fraumeni syndrome?Journal of Medical Genetics, 2008
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 2005
- Neurofibromatosis 2Current Opinion in Neurology, 2003